Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H22FN7O |
| Molecular Weight | 467.4976 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=C(C)C=C1C(=O)NC2=C(F)C=CC(NC3=CC=C4C(NN=C4\C=C\C5=CC=CC=N5)=C3)=C2
InChI
InChIKey=JXSVVZKPEDIRTN-DHZHZOJOSA-N
InChI=1S/C26H22FN7O/c1-16-13-25(34(2)33-16)26(35)30-24-15-19(7-10-21(24)27)29-18-6-9-20-22(31-32-23(20)14-18)11-8-17-5-3-4-12-28-17/h3-15,29H,1-2H3,(H,30,35)(H,31,32)/b11-8+
| Molecular Formula | C26H22FN7O |
| Molecular Weight | 467.4976 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator​
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [IC50 1 uM] | ||||
| yes [IC50 1.5 uM] | ||||
| yes [IC50 10 uM] | ||||
| yes [IC50 11 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| minimal |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:39 GMT 2025
by
admin
on
Mon Mar 31 18:13:39 GMT 2025
|
| Record UNII |
BK72RP7F7D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3545335
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY | |||
|
9934283
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY | |||
|
BK72RP7F7D
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY | |||
|
DTXSID20953842
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY | |||
|
N-(2-FLUORO-5-((3-((1E)-2-(2-PYRIDINYL)ETHENYL)-1H-INDAZOL-6-YL)AMINO)PHENYL)-1,3-DIMETHYL-1H-PYRAZOLE-5-CARBOXAMIDE
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY | SYN-1004, CAS 319460-94-1: AG13958 is a VEGF inhibitor that was clinical development by Pfizer in 2006-07 for treatment of age-related macular degeneration (AMD). The drug displays low water solubility and so far in trials delivery has been difficult needing direct injection to be truly effective and it varied by the species used because of species specific differences in eye circulation and vascularization. As a VEGF inhibitor AG13958 was targeted to FLT/TYK receptor inhibition. | ||
|
319460-94-1
Created by
admin on Mon Mar 31 18:13:39 GMT 2025 , Edited by admin on Mon Mar 31 18:13:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Eye disorder therapy; Mechanism of Action: Angiogenesis inhibitor, Vascular endothelial growth factor A inhibitor; Highest Development Phase: Discontinued for Age-related macular degeneration; Most Recent Events: 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in Australia (Ophthalmic), 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in United Kingdom (Ophthalmic), 11 Mar 2008 Discontinued - Phase-I/II for Age-related macular degeneration in Netherlands (Ophthalmic)
|
